 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
26 News |  |
- | SOR C13 / Soricimed
Trial completion, Enrollment change, Metastases: A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 23, 2023
P1, N=11, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=36 --> 11
- | SOR C13 / Soricimed
Trial completion date, Trial primary completion date, Metastases: A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 24, 2022
P1, N=36, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=36 --> 11 Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- || SOR C13 / Soricimed
Clinical, Journal: Methylome profiling of young adults with depression supports a link with immune response and psoriasis. (Pubmed Central) - Aug 20, 2021
Our data suggests an immune component to the aetiology of depression in at least a small subgroup of cases, consistent with the accumulating evidence supporting a relationship between inflammation and depression. Additionally, DNA methylation changes at key loci, detected in saliva, may represent a valuable tool for identifying at-risk subjects.
- SOR C13 / Soricimed
[VIRTUAL] Soricimed Biopharma Inc. () - May 31, 2021 - Abstract #BIO2021BIO_517;
The Company’s lead drug candidate, SOR-C13, is a first-in-class selective inhibitor of TRPV6 - a calcium channel over-expressed by solid tumour cancers...Soricimed recently launched a collaboration to develop a targeted peptide receptor radiotherapy (PRRT). Finally, Soricimed has successfully constructed peptide-drug conjugates (PDCs) that specifically target cancer cells by way of binding to TRPV6.
- SOR C13 / Soricimed
[VIRTUAL] A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_878;
P1
Funding: NCI. Clinical trial identification: NCT03784677.
- SOR C13 / Soricimed
YEAST PHENOMIC ANALYSIS OF RPL12 EPISTASIS IN THE RESCUE OF F670DEL-YOR1 MISFOLDING () - Nov 11, 2019 - Abstract #NACFC2019NACFC_18;
Other GO-enriched and non-GO-enriched genes in both deletion enhancing and suppressing interaction categories were additionally informative about biological processes that alternately promote or impede deltaF biogenesis. (Supported by CFF (SORSCH13XXO; HARTMA155G0) and NIH (R01HL136414).)
- SOR C13 / Soricimed
PARTIAL RESCUE OF G542X- AND W1282X-CFTR IS ACHIEVED FOLLOWING SUPPRESSION OF SPECIFIC RIBOSOMAL COMPONENTS () - Nov 11, 2019 - Abstract #NACFC2019NACFC_14;
Taken together, our results establish relevance of the yeast phenomics model and indicate specific ribosomal proteins – Rpl8 or Rpl12 in particular – should be considered as novel therapeutic targets for overcoming CFTR PTCs. (Supported by CFF (OLIVER17F0; IGNATO17XXO; SORSCH13XXO; HARTMA16G0), Burroughs Wellcome Fund (2018 CRTG) and NIH (R01HL136414).)
- SOR C13 / Soricimed
EPISTATIC EFFECTS OF COMPLEX ALLELES ON CYSTIC FIBROSIS PHENOTYPE – A PROTEIN TRANSLATIONAL PERSPECTIVE () - Nov 11, 2019 - Abstract #NACFC2019NACFC_12;
Epistatic interactions such as these may have greater impact on CF disease severity and efficacy of pharmacologic intervention than previously appreciated. (Supported by CFF (SORSCH13XXO, IGNATO17XXO OLIVER17F0), Muko e.V Germany (1603), DFG (1805), NIH USA (R01HL138414).)
- | SOR C13 / Soricimed
Enrollment open, Metastases: A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 1, 2019
P1, N=36, Recruiting, Sponsor: M.D. Anderson Cancer Center
(Supported by CFF (SORSCH13XXO, IGNATO17XXO OLIVER17F0), Muko e.V Germany (1603), DFG (1805), NIH USA (R01HL138414).) Not yet recruiting --> Recruiting
- | SOR C13 / Soricimed
New P1 trial, Metastases: A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 24, 2018
P1, N=36, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | SOR C13 / Soricimed
Preclinical, Journal: Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. (Pubmed Central) - Sep 15, 2018
TRPV6 mRNA and protein are elevated in biopsies of ovarian cancers compared to normal tissue. Inhibition of TRPV6 activity significantly reduces ovarian tumour growth providing evidence that TRPV6 is a feasible oncology target in ovarian cancers.
- | SOR C13 / Soricimed
Clinical, P1 data, Journal: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. (Pubmed Central) - Mar 23, 2018
The Maximal Tolerated Dose (MTD) was not established. Stable disease suggested antitumor activity.
- | SOR C13 / Soricimed
Trial completion, Enrollment change, Metastases: Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel (clinicaltrials.gov) - Jun 23, 2016
P1, N=23, Completed, Sponsor: Soricimed Biopharma Inc
Stable disease suggested antitumor activity. Recruiting --> Completed | N=30 --> 23
- SOR C13 / Soricimed
Trial primary completion date, Metastases: Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel (clinicaltrials.gov) - Dec 5, 2014
P1, N=30, Recruiting, Sponsor: Soricimed Biopharma Inc
Recruiting --> Completed | N=30 --> 23 Trial primary completion date: Mar 2014 --> Jul 2015
- SOR C13 / Soricimed
Enrollment open, Metastases: Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel (clinicaltrials.gov) - Jul 24, 2012
P1, N=30, Recruiting, Sponsor: Soricimed Biopharma Inc
Trial primary completion date: Mar 2014 --> Jul 2015 Not yet recruiting --> Recruiting
- | SOR C13 / Soricimed
New P1 trial, Metastases: Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel (clinicaltrials.gov) - Apr 15, 2012
P1, N=30, Recruiting, Sponsor: Soricimed Biopharma Inc